BridgeMD
Pathophysiology of pain in Parkinson's disease: exploration of the serotonin system in positron emission tomography
EU CTIS ID: 2022-501123-24-00
What this study is testing
The primary endpoint is the distribution volume ratio of [18F]-MPPF (DVR) using the cerebellum as the reference region, measured in both groups of painful and non-painful PD patients
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients with Parkinson's disease defined according to UKPDSBB criteria
- Men and women aged between 35 and 85 years
- Patients with stable anti-parkinsonian treatment for at least 2 weeks prior to V2
- Patients with a MOCA score ≥ 24
- Patients with a HADS-D score ≤ 11
- Person affiliated or benefiting from a social security scheme.
You likely can't join if
- Patients treated with second line therapy (deep brain stimulation, pump - duodopa and apokinon)
- Patients with a history of significant psychiatric pathology according to the investigator
- Patients treated with drugs interacting with 5HT1A receptors in the previous 2 weeks ( serotonergic antidepressants)
- Patients with contraindication to MRI
- Patients refusing to be informed of an abnormality discovered during brain imaging
- Patients with dyskinesias judged by the investigator to be disabling for imaging
See the full eligibility criteria
- Patients with Parkinson's disease defined according to UKPDSBB criteria
- Men and women aged between 35 and 85 years
- Patients with stable anti-parkinsonian treatment for at least 2 weeks prior to V2
- Patients with a MOCA score ≥ 24
- Patients with a HADS-D score ≤ 11
- Person affiliated or benefiting from a social security scheme.
- Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).
- Patients treated with second line therapy (deep brain stimulation, pump - duodopa and apokinon)
- Patients with a history of significant psychiatric pathology according to the investigator
- Patients treated with drugs interacting with 5HT1A receptors in the previous 2 weeks ( serotonergic antidepressants)
- Patients with contraindication to MRI
- Patients refusing to be informed of an abnormality discovered during brain imaging
- Patients with dyskinesias judged by the investigator to be disabling for imaging
- Patients under guardianship or other legal protection, deprived of their liberty by judicial or administrative decision
- Pregnant woman, breastfeeding woman
- Triptans taken in the 48 hours preceding PET
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.